heat shock protein 90 alpha family class B member 7, pseudogeneGenealiases: []
Q-omics provides the consensus-scored HSP90AB7P profile across patient tissues and cancer cell-line models. HSP90AB7P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HSP90AB7P is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, HSP90AB7P RNA expression shows 6,354 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where HSP90AB7P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSP90AB7P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSP90AB7P survival associations across molecular data types. HSP90AB7P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSP90AB7P RNA expression–survival associations across cancer types. High HSP90AB7P expression shows unfavorable associations in KIRC, LIHC, KIRP, DLBC and MESO, but favorable associations in LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for HSP90AB7P RNA expression.
This table summarizes HSP90AB7P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HSP90AB7P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSP90AB7P shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, BRCA, HNSC and PRAD. The COAD box plot shows higher HSP90AB7P RNA expression in tumor versus normal tissue (log2 FC = +0.056, t-test p = .002).
This table shows molecular features associated with HSP90AB7P in patient tissues and cancer cell lines. In patient samples, HSP90AB7P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
